Growth hormone and tesamorelin in the management of HIV-associated lipodystrophy
Roger BedimoInfectious Disease section, VA North Texas Health Care System, TX, USAAbstract: HIV-infected patients on highly active antiretroviral therapy (HAART) develop a complex of body composition changes known, including peripheral fat loss (lipoatrophy) and central fat accumulation (lipohypertr...
Saved in:
Main Author: | Bedimo R |
---|---|
Format: | article |
Language: | EN |
Published: |
Dove Medical Press
2011
|
Subjects: | |
Online Access: | https://doaj.org/article/077f68c999454baf9a932f0acba231b4 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Lipodystrophy in HIV patients: its challenges and management approaches
by: Singhania R, et al.
Published: (2011) -
New and emerging agents in the management of lipodystrophy in HIV-infected patients
by: Eric Bonnet
Published: (2010) -
Role of darunavir in the management of HIV infection
by: R Monica Lascar, et al.
Published: (2009) -
Role of raltegravir in the management of HIV-1 infection
by: Okeke NL, et al.
Published: (2011) -
Profile of darunavir in the management of treatment-experienced HIV patients
by: Cameron Wolfe, et al.
Published: (2009)